What is Omniose?
Founded in 2017 as VaxNewMo, Omniose operates at the intersection of synthetic biology and immunology. The company leverages pioneering research into conjugating enzymes to create highly effective vaccine candidates. By utilizing a platform technology that facilitates the precise attachment of glycans to proteins, Omniose is uniquely positioned to tackle challenging targets such as Group B Streptococcus and Klebsiella pneumoniae. The firm's evolution from an accelerator-backed startup at BioGenerator Labs to a sophisticated enterprise-level entity reflects its successful transition from academic discovery to industrial-scale application.
How much funding has Omniose raised?
Omniose has raised a total of $3.6M across 1 funding round:
Grant
$3.6M
Grant (2022): $3.6M with participation from U.S. National Institutes of Health
Key Investors in Omniose
U.S. National Institutes of Health
A federal agency responsible for biomedical and public health research, providing critical grant funding to support high-impact scientific innovation.
What's next for Omniose?
With this recent capital injection, Omniose is poised to accelerate its clinical development pipeline and expand its research operations. The strategic focus will likely remain on scaling the production of its platform technology to meet the rigorous demands of regulatory approval processes. As the company continues to refine its glycoconjugation methodologies, it is expected to seek further partnerships or licensing agreements to broaden the therapeutic reach of its vaccine portfolio, ultimately aiming to address significant unmet needs in global public health.
See full Omniose company page
